High Court Won’t Hear Sheller Dispute with FDA over Risperdal
High Court Won’t Hear Dispute Challenging FDA Over J&J Drug Supreme Court won’t weigh in on whether law firm can sue FDA over drug labeling Circumstances in which third parties can sue over government actions remain unclear By Dana A. Elfin A Philadelphia-based law firm has hit the end of the road in its bid […]
$70M Risperdal Verdict
In the Philly Inquirer July 2, 2016: Philadelphia jury pins $70m verdict on Janssen for its Risperdal drug A Philadelphia jury found Friday that the antipsychotic drug Risperdal caused a Tennessee boy to grow breasts and imposed a $70 million verdict on its manufacturer, Janssen Pharmaceuticals. Lawyers for the boy argued that scientists for the […]
Risperdal News: Sheller Quoted in Toronto Star
Stephen Sheller was quoted in a July 31, 2015 article discussing Risperdal research that was “manipulated by a drug company and understated the risks of a powerful antipsychotic used to treat kids with behavioural problems.” In the news story, pediatrician Denis Daneman says there was no intent on his part to exclude “significant results” from […]
#1 PA V&S 2013-2014
Sheller, P.C. had the largest settlement in Pennsylvania in 2013-2014 as published in American Lawyer Media’s Legal Intelligencer newspaper. The $2.2 billion settlement with Janssen Pharmaceuticals, a division of Johnson & Johnson, was a qui tam case where Sheller, P.C. represented the whistleblower who brought the qui tam charges. With the U.S. Department of Justice, […]
Sheller in Bloomberg Business on Whistleblowers and J&J $2.2B Settlement
Bloomberg Business Week 2013-12-09 Judy Doetterl was a sales representative for Johnson & Johnson (JNJ) in 2004 when federal agents placed a hidden recording device on her and sent her to tape marketing presentations at a national company sales meeting. U.S. prosecutors wanted to prove claims by Doetterl and others that J&J boosted sales by urging doctors to prescribe […]
Sheller in Philadelphia Inquirer on $2.2B Risperdal Settlement
Philadelphia Inquirer 2013-11-05 Sheller, P.C.’s representation of whistleblowers totals over $6 billion, with three of the top five pharmaceutical settlements in history: 2009: Pfizer $2.3 billion (Geodon) 2009: Eli Lilly & Co. $1.4 billion (Zyprexa) 2013: Johnson & Johnson $2.2 billion (Risperdal, Invega) and in 2010 : Astra Zeneca $520 million (Seroquel) WASHINGTON – Health-care […]
Sheller on Lawyer Spars With FDA Over J&J Risperdal Court Documents
Pharmalot.com, Pharmaceutical Industry News 2013-07-11 In an unusual tactic, an attorney is prodding the FDA to seek documents that purportedly detail side effects caused by the Risperdal antipsychotic, but cannot be released publicly due to a court order. The documents were sealed by a Philadelphia judge as part of ongoing litigation over claims the Johnson […]
